Meeta Gulyani to join Merck Serono on 7 May

Will become Head of Strategy and Global Franchises

Merck Serono, the biopharmaceuticals division of Merck, has appointed Meeta Gulyani as Head of Strategy and Global Franchises. She joins the company on 7 May and will be based in Boston, US, reporting to Belén Garijo, President and Chief Executive of Merck Serono.

Gulyani will lead Merck Serono’s Global Franchises (Multiple Sclerosis & Immunology, Oncology, Fertility, General Medicine & Endocrinology, and Medical Devices).

With Gulyani’s appointment, and further to the promotion of Elcin Ergun on 1 January as Head of Commercial, Merck Serono’s Pharmaceutical Executive Committee is now complete.

Gulyani joins Merck Serono from Roche where she was most recently General Manager for South Asia, covering India, Sri Lanka, Bangladesh and Nepal, and previously Vice President of Global Portfolio Management.

Prior to joining Roche in 2010, Gulyani spent eight years at Sanofi.

You may also like

Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Manufacturing

Merck and Daiichi Sankyo expand antibody drug conjugate commercialisation agreement

The companies will collaborate to commercialise MK-6070, a T-cell engager which has shown promise in treating patients with small cell lung cancer (SCLC)
Drug Delivery

Merck launches VirusExpress platform for cell and gene therapies

The platform helps to overcome lentiviral production challenges and can reduce process development time by approximately 40%, Merck says
Manufacturing

Achieve greater upstream productivity with intensified processing

New App Note from Merck on the use of perfusion technologies
Pharmaceutical

Evotec agrees to give US Merck access to facility of the future

MSD has paid $15m to gain access to Just–Evotec Biologics’ J.POD Washington facility that conducts small, intensified bioprocessing operations housed inside autonomous cleanrooms
Pharmaceutical

US Merck backs college course to create workforce for $1bn expansion

The curriculum will focus on biotechnology, process engineering and workforce development to create a ready made workforce to fill 100 new jobs at expanding Virginia facility
Subscribe now